Sun Pharma flags mixed Fibromun trial results, advances new Phase III study in soft tissue sarcoma

The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy

Kauvery Hospital sets new benchmark in high-risk cardiac care

71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day

Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData

Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning

Alembic Pharmaceuticals partners with Enthral.ai for learning and training management of its 9000+ learners

Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows

Orca Bio’s Orca-T FDA review extended to July 2026

Bristol Myers Squibb expands groundbreaking program to close faps in multiple myeloma care

The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners

Otsuka Pharma to acquire Transcend Therapeutics in $1.225 billion deal

Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones

ImmunityBio scores first Asian approval for ANKTIVA in Macau

The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency

Bristol Myers Squibb scores major win with new Opdivo nods for Hodgkin Lymphoma in US, EU

These approvals represent a defining moment for people living with classical Hodgkin Lymphoma

Roche unveils massive AI factory to supercharge drug development

The facility features 2,176 high-performance GPUs across the US and Europe